Innate Pharma (IPHYF) Profit After Tax (2019 - 2022)

Innate Pharma's Profit After Tax history spans 4 years, with the latest figure at -$59.3 million for Q4 2022.

  • For Q4 2022, Profit After Tax rose 1.87% year-over-year to -$59.3 million; the TTM value through Dec 2022 reached -$59.3 million, up 1.87%, while the annual FY2025 figure was -$57.2 million, 6.91% down from the prior year.
  • Profit After Tax reached -$59.3 million in Q4 2022 per IPHYF's latest filing, up from -$60.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$23.0 million in Q4 2019 to a low of -$76.3 million in Q4 2020.
  • Average Profit After Tax over 4 years is -$54.7 million, with a median of -$59.8 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: tumbled 232.0% in 2020, then grew 20.81% in 2021.
  • A 4-year view of Profit After Tax shows it stood at -$23.0 million in 2019, then crashed by 232.0% to -$76.3 million in 2020, then increased by 20.81% to -$60.4 million in 2021, then increased by 1.87% to -$59.3 million in 2022.
  • Per Business Quant, the three most recent readings for IPHYF's Profit After Tax are -$59.3 million (Q4 2022), -$60.4 million (Q4 2021), and -$76.3 million (Q4 2020).